ArticleMolecular pharmaceutics2023
Defining the Intravital Renal Disposition of Fluorescence-Quenched Exenatide.
Mark A Bryniarski, Ruben M Sandoval, Donna M Ruszaj, John Fraser-McArthur, Benjamin M Yee, Rabi Yacoub, Lee D Chaves, Silvia B Campos-Bilderback, Bruce A Molitoris, Marilyn E Morris
Open access · greenAbstract read
In one paragraphArticle in Molecular pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 3 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
10 authors at 3 institutions in 1 country.
Mark A BryniarskiDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 304 Pharmacy Building, Buffalo, New York 14215, United States.ORCID 0000-0003-0572-0560 Ruben M SandovalDepartment of Medicine, Indiana University, Indianapolis, Indiana 46202, United States.
Donna M RuszajDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 304 Pharmacy Building, Buffalo, New York 14215, United States.
John Fraser-McArthurDepartment of Pharmacy, University of Rochester Medical Center, Rochester, New York 14642, United States.
Benjamin M YeeDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 304 Pharmacy Building, Buffalo, New York 14215, United States.
Rabi YacoubDepartment of Internal Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14203, United States.
Lee D ChavesDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 304 Pharmacy Building, Buffalo, New York 14215, United States.ORCID 0000-0001-9922-5012 Silvia B Campos-BilderbackDepartment of Medicine, Indiana University, Indianapolis, Indiana 46202, United States.
Bruce A MolitorisDepartment of Medicine, Indiana University, Indianapolis, Indiana 46202, United States.
Marilyn E MorrisDepartment of Pharmaceutical Sciences, School of Pharmacy and Pharmaceutical Sciences, University at Buffalo, 304 Pharmacy Building, Buffalo, New York 14215, United States.ORCID 0000-0003-1127-7964 University at Buffalo, State University of New York · USIndiana University – Purdue University Indianapolis · USUniversity of Rochester Medical Center · US
Funding
PROBE DELIVERY COREP30DK079312 · NIDDK · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI MOLITORIS, BRUCE A · 2007 to 2021
$17.1MProximal Tubule Albumin Transport in Disease States.R01DK091623 · NIDDK · INDIANA UNIVERSITY INDIANAPOLIS · PI MOLITORIS, BRUCE A · 2011 to 2021
$4.3MNIDDK NIH HHS P30 DK079312NIDDK NIH HHS R01 DK091623
6 · The paper itselfAbstract
Despite the understanding that renal clearance is pivotal for driving the pharmacokinetics of numerous therapeutic proteins and peptides, the specific processes that occur following glomerular filtration remain poorly defined. For instance, sites of catabolism within the proximal tubule can occur at the brush border, within lysosomes following endocytosis, or even within the tubule lumen itself. The objective of the current study was to address these limitations and develop methodology to study the kidney disposition of a model therapeutic protein. Exenatide is a peptide used to treat type 2 diabetes mellitus. Glomerular filtration and ensuing renal catabolism have been shown to be its principal clearance pathway. Here, we designed and validated a Förster resonance energy transfer-quenched exenatide derivative to provide critical information on the renal handling of exenatide. A combination of
Indexed as
Diabetes Mellitus, Type 2ExenatideKidneyAnimalsKidney Tubules, ProximalPeptidesRatsExenatidePeptidesFRETintravital two-photon microscopyrenal metabolism
Identifiers
PMID36626167
PMCPMC9907348
OpenAlexW4314434819
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390